OUR MANAGEMENT TEAM
Alan Tuchman, MD, MBA
Alan Tuchman, MD, MBA, is the managing director at MedPro Investors.
He brings over 35 years of medical experience, and a wealth of healthcare
Dr. Tuchman’s successful tenure in the medical and investment fields include his reign as Executive Chairman at Neurophysics, Inc., a manufacturer of nuclear brain scanners; Managing Director of Xmark Funds, a biotechnology investment firm; and Principal of his own healthcare consulting firm.
Dr. Tuchman is a clinical professor of neurology at New York Medical College and is in private practice in Manhattan.
Steve Nagler is a lawyer who has been engaged in healthcare investment for
30 years. He has been active in the venture capital and angel investing
communities and maintains strong contacts in both. He has served as
General Counsel of Patlex Corporation, where he managed the successful
licensing program for the company’s heavily contested seminal patents covering the laser. He also served as Executive Director of the National Constitution Center and the American Bar Association’s Commission on Public Understanding of the Law, among many other public interest activities. He spent two years as a Peace Corps Volunteer in Malawi, Africa.
Isaac Treitel has over fifteen years experience identifying promising early-stage
life science and technology companies and providing them with development
and financial support. As a Director of TriState Ventures and co-founder of
MedPro Investors LLC, Isaac evaluates investment opportunities, develops
strategic partnerships, and advises portfolio companies on operational and financial strategy. His prior experience includes webtool and software development, as well as investment analysis. Isaac began his career as a Research Analyst for a large pension fund before focusing on what he found most rewarding, the nurturing and financing of smaller companies.
Mitchell Glass, MD
Dr. Mitchell Glass is a 25 year veteran of the pharmaceutical industry.
His experience includes senior positions at top ten pharmaceutical companies,
as well as investment in and management of start-ups and biotechs.
After seven years of research, teaching and patient care at the University of Pennsylvania, Dr. Glass joined ICI Pharmaceuticals in 1988 where he established the pulmonary therapeutics group and led the development and submission of the antileukotriene ACCOLATE®. From 1995 to 1996, Dr. Glass was Vice President and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, including submission of the NDA/MAA for COREG®. From 1998 to 2003, Dr. Glass was Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics Inc. (AGIX), where he led product development from IND to initiation of Phase 3 for AGI1067 and was a member of the IPO team. Dr. Glass later joined AQUMEN Biopharmaceuticals KK and NA as CEO of AQUMEN NA and currently serves as Executive VP R&D and Chief Medical Officer of Invion Limited. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.
Geoff McGrane, MBA
Geoff McGrane has a combined eight years of finance and life science
Geoff was formerly a leveraged finance research analyst at Standard &
Poor's, where he spearheaded development of the company's high yield bond research platform, and is currently Director of Business Development at the New York Stem Cell Foundation. Geoff holds an MBA from Columbia Business School and a bachelor's degree in Economics from NYU, where he graduated with honors. He is an avid distance runner who has completed a number of marathons, including five as part of a "duo team" in which he pushed a disabled participant in a wheelchair.
Tim Hirst, PhD
Ray Whitaker, PhD
Tom DiBartholomeo, MD